Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi, Amy L. Adlard, Grazyna Lipowska‐Bhalla, et al.
Cancer Research (2014) Vol. 74, Iss. 19, pp. 5458-5468
Open Access | Times Cited: 1153

Showing 1-25 of 1153 citing articles:

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 21, pp. 2018-2028
Open Access | Times Cited: 5638
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 20, pp. 1919-1929
Open Access | Times Cited: 3826
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei, Colm R. Duffy, James P. Allison
Cancer Discovery (2018) Vol. 8, Iss. 9, pp. 1069-1086
Open Access | Times Cited: 2588
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 24, pp. 2342-2350
Open Access | Times Cited: 2474
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou, Jedd D. Wolchok, Lieping Chen
Science Translational Medicine (2016) Vol. 8, Iss. 328
Open Access | Times Cited: 2129
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney, Paul D. Rennert, Gordon J. Freeman
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 8, pp. 561-584
Closed Access | Times Cited: 1200
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum, Hua Liang, Liufu Deng, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 6, pp. 365-379
Closed Access | Times Cited: 878
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth, Shin Foong Ngiow, Antoni Ribas, et al.
Nature Reviews Clinical Oncology (2015) Vol. 13, Iss. 3, pp. 143-158
Closed Access | Times Cited: 845
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
Willemijn S.M.E. Theelen, Heike Peulen, Ferry Lalezari, et al.
JAMA Oncology (2019) Vol. 5, Iss. 9, pp. 1276-1276
Open Access | Times Cited: 782
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi, Michael Lim, Theodore L. DeWeese, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 13, pp. e498-e509
Closed Access | Times Cited: 772
Role of Local Radiation Therapy in Cancer Immunotherapy
Sandra Demaria, Encouse B. Golden, Silvia C. Formenti
JAMA Oncology (2015) Vol. 1, Iss. 9, pp. 1325-1325
Closed Access | Times Cited: 652
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
Encouse B. Golden, Arpit M. Chhabra, Abraham Chachoua, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 7, pp. 795-803
Closed Access | Times Cited: 605
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Andrew B. Sharabi, Christopher J. Nirschl, Christina M. Kochel, et al.
Cancer Immunology Research (2014) Vol. 3, Iss. 4, pp. 345-355
Open Access | Times Cited: 593
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato, Atsuko Niimi, Takaaki Yasuhara, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 589
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, et al.
Cancer Discovery (2017) Vol. 7, Iss. 7, pp. 675-693
Open Access | Times Cited: 581
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
Kobe Reynders, Tim Illidge, Shankar Siva, et al.
Cancer Treatment Reviews (2015) Vol. 41, Iss. 6, pp. 503-510
Open Access | Times Cited: 523
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok
Cancer Cell (2018) Vol. 33, Iss. 4, pp. 581-598
Open Access | Times Cited: 467
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y. Lee, Robert L. Ferris, Amanda Psyrri, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 4, pp. 450-462
Closed Access | Times Cited: 440
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan, Dong Zhang, Chunxiao Xu, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 424
Open Access | Times Cited: 431
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
Alexander Filatenkov, Jeanette Baker, Antonia M.S. Mueller, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 16, pp. 3727-3739
Open Access | Times Cited: 413
Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
María E. Rodríguez-Ruiz, Claire Vanpouille‐Box, Ignacio Melero, et al.
Trends in Immunology (2018) Vol. 39, Iss. 8, pp. 644-655
Open Access | Times Cited: 407
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Yang Liu, Yinping Dong, Li Kong, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 381
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He, Ying Hu, Mingming Hu, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 376
Current clinical trials testing the combination of immunotherapy with radiotherapy
Josephine Kang, Sandra Demaria, Silvia C. Formenti
Journal for ImmunoTherapy of Cancer (2016) Vol. 4, Iss. 1
Open Access | Times Cited: 354
Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
Yifan Wang, Weiye Deng, Nan Li, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 332
Page 1 - Next Page

Scroll to top